Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Alumis Inc. Common StockNASDAQ: ALMS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $23.36M rose 8.9% year over year, behind the +17.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 25.5% from the prior quarter. Over 3 fiscal years it compounded at +94.2% a year.
Context
- Selling, general & admin amounted to 381.9% of revenue in FY2025.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $12.23M (-86.7%) for the fiscal year ending Dec 2026, a slowdown from the +161.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $23.36M+25.5% QoQ
- Last fiscal yearDec 2025
- $91.86M+161.0% YoY
- LTMJun 2026
- $77.08M+17.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 91.86M USD
- Year-over-year change
- +161.0%
- 3-year CAGR
- +94.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.86M | +161.0% |
| FY2024 | 2024-12-31 | 35.2M | +71.7% |
| FY2023 | 2023-12-31 | 20.5M | +63.4% |
| FY2022 | 2022-12-31 | 12.55M | — |
Selling, General & Admin vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.2% is the 5th highest of 10, against a peer median of +8.2%.
- Selling, general & admin amounts to 1041.9% of revenue for ALMS, versus a peer median of 269.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.14T USD | +9732467.6% | -14.5% | — | |
| LTM Mar 2026 | $118.84M USD | +5.8% | +1.0% | 39.6% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M USD | +17.2% | +94.2% | 1041.9% |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $24.19M USD | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M USD | +8.2% | -0.8% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| FY2025 | $10.77M USD | +4.7% | +31.3% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €9.82M EUR | +63.8% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +8.2% | +2.2% | 269.8% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | 250K | 0 | 3.15M | 3.5M |
| Gross Profit | (250K) | 0 | (3.15M) | 20.55M |
| Gross Margin | — | — | — | 85.5% |
| Research & Development | 101.05M | 137.68M | 265.55M | 386M |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M | 91.86M |
| Operating Expenses | 113.6M | 158.17M | 297.6M | 447.76M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| EBITDA | (111.68M) | (153.71M) | (291.08M) | (248.39M) |
| EBITDA Margin | — | — | — | -1032.8% |
| Operating Income | (113.85M) | (158.17M) | (300.75M) | (427.2M) |
| Operating Margin | — | — | — | -1776.3% |
| Interest Income | 1.99M | 3.37M | 12.02M | 14.18M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | 3.18M | 6.52M | 175.32M |
| Income Before Tax | (111.93M) | (154.99M) | (294.23M) | (251.89M) |
| Pre-Tax Margin | — | — | — | -1047.3% |
| Income Tax Expense | 0 | 0 | 0 | (8.56M) |
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Net Margin | — | — | — | -1011.7% |
| EPS (Basic) | (14.93) | (2.99) | (10.38) | (2.32) |
| EPS (Diluted) | (14.93) | (2.99) | (10.38) | (2.32) |
| Weighted Avg Shares | 7.5M | 51.84M | 28.34M | 850.3M |
| Weighted Avg Shares (Diluted) | 7.5M | 51.84M | 28.34M | 850.3M |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.